Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug
Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a coronavirus (MERS-CoV). Since its emergence in 2012, nosocomial amplifications have led to its high epidemic potential and mortality rate of 34.5%. To date, there is an unmet need for vaccines and specific therapeutics for...
Saved in:
Main Authors: | , , , , , , , , |
---|---|
Other Authors: | |
Format: | Article |
Language: | English |
Published: |
2022
|
Subjects: | |
Online Access: | https://hdl.handle.net/10356/159916 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Institution: | Nanyang Technological University |
Language: | English |
id |
sg-ntu-dr.10356-159916 |
---|---|
record_format |
dspace |
spelling |
sg-ntu-dr.10356-1599162022-07-05T08:44:33Z Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug Gan, Hanjie Jonathan Harikishore, Amaravadhi Lee, Jihye Jeon, Sangeun Rajan, Sreekanth Chen, Ming Wei Neo, Jun Long Kim, Seungtaek Yoon, Ho Sup School of Biological Sciences Science::Biological sciences MERS-CoV Receptor-Binding Domain Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a coronavirus (MERS-CoV). Since its emergence in 2012, nosocomial amplifications have led to its high epidemic potential and mortality rate of 34.5%. To date, there is an unmet need for vaccines and specific therapeutics for this disease. Available treatments are either supportive medications in use for other diseases or those lacking specificity requiring higher doses. The viral infection mode is initiated by the attachment of the viral spike glycoprotein to the human Dipeptidyl Peptidase IV (DPP4). Our attempts to screen antivirals against MERS led us to identify montelukast sodium hydrate (MSH), an FDA-approved anti-asthma drug, as an agent attenuating MERS-CoV infection. We showed that MSH directly binds to MERS-CoV-Receptor-Binding Domain (RBD) and inhibits its molecular interaction with DPP4 in a dose-dependent manner. Our cell-based inhibition assays using MERS pseudovirions demonstrated that viral infection was significantly inhibited by MSH and was further validated using infectious MERS-CoV culture. Thus, we propose MSH as a potential candidate for therapeutic developments against MERS-CoV infections. Nanyang Technological University National Research Foundation (NRF) This study was supported by Research Student Scholarship from Nanyang Technological University Singapore (given to H.J. Gan), NRF2017M3A9G6068245, and CRC-16-01-KRICT. 2022-07-05T08:44:33Z 2022-07-05T08:44:33Z 2021 Journal Article Gan, H. J., Harikishore, A., Lee, J., Jeon, S., Rajan, S., Chen, M. W., Neo, J. L., Kim, S. & Yoon, H. S. (2021). Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug. Antiviral Research, 185, 104996-. https://dx.doi.org/10.1016/j.antiviral.2020.104996 0166-3542 https://hdl.handle.net/10356/159916 10.1016/j.antiviral.2020.104996 33309540 2-s2.0-85097801797 185 104996 en NRF2017M3A9G6068245 Antiviral Research © 2020 Elsevier B.V. All rights reserved. |
institution |
Nanyang Technological University |
building |
NTU Library |
continent |
Asia |
country |
Singapore Singapore |
content_provider |
NTU Library |
collection |
DR-NTU |
language |
English |
topic |
Science::Biological sciences MERS-CoV Receptor-Binding Domain |
spellingShingle |
Science::Biological sciences MERS-CoV Receptor-Binding Domain Gan, Hanjie Jonathan Harikishore, Amaravadhi Lee, Jihye Jeon, Sangeun Rajan, Sreekanth Chen, Ming Wei Neo, Jun Long Kim, Seungtaek Yoon, Ho Sup Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug |
description |
Middle East Respiratory Syndrome (MERS) is a respiratory disease caused by a coronavirus (MERS-CoV). Since its emergence in 2012, nosocomial amplifications have led to its high epidemic potential and mortality rate of 34.5%. To date, there is an unmet need for vaccines and specific therapeutics for this disease. Available treatments are either supportive medications in use for other diseases or those lacking specificity requiring higher doses. The viral infection mode is initiated by the attachment of the viral spike glycoprotein to the human Dipeptidyl Peptidase IV (DPP4). Our attempts to screen antivirals against MERS led us to identify montelukast sodium hydrate (MSH), an FDA-approved anti-asthma drug, as an agent attenuating MERS-CoV infection. We showed that MSH directly binds to MERS-CoV-Receptor-Binding Domain (RBD) and inhibits its molecular interaction with DPP4 in a dose-dependent manner. Our cell-based inhibition assays using MERS pseudovirions demonstrated that viral infection was significantly inhibited by MSH and was further validated using infectious MERS-CoV culture. Thus, we propose MSH as a potential candidate for therapeutic developments against MERS-CoV infections. |
author2 |
School of Biological Sciences |
author_facet |
School of Biological Sciences Gan, Hanjie Jonathan Harikishore, Amaravadhi Lee, Jihye Jeon, Sangeun Rajan, Sreekanth Chen, Ming Wei Neo, Jun Long Kim, Seungtaek Yoon, Ho Sup |
format |
Article |
author |
Gan, Hanjie Jonathan Harikishore, Amaravadhi Lee, Jihye Jeon, Sangeun Rajan, Sreekanth Chen, Ming Wei Neo, Jun Long Kim, Seungtaek Yoon, Ho Sup |
author_sort |
Gan, Hanjie Jonathan |
title |
Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug |
title_short |
Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug |
title_full |
Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug |
title_fullStr |
Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug |
title_full_unstemmed |
Antiviral activity against Middle East Respiratory Syndrome coronavirus by Montelukast, an anti-asthma drug |
title_sort |
antiviral activity against middle east respiratory syndrome coronavirus by montelukast, an anti-asthma drug |
publishDate |
2022 |
url |
https://hdl.handle.net/10356/159916 |
_version_ |
1738844828430499840 |